Literature DB >> 16775569

Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction.

Alexander Geppert1, Angela Dorninger, Georg Delle-Karth, Gerlinde Zorn, Gottfried Heinz, Kurt Huber.   

Abstract

OBJECTIVE: Inflammation may play an important role in the pathogenesis, persistence, and prognosis of cardiogenic shock. We analyzed whether elevated plasma concentrations of inflammatory markers are independently associated with an adverse prognosis (increased 30-day mortality rate) in patients with cardiogenic shock.
DESIGN: Retrospective study.
SETTING: Single-center study, eight-bed intensive care unit at a university hospital. PATIENTS: Retrospective study on stored plasma samples from 38 patients with cardiogenic shock complicating acute myocardial infarction.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Thirty-day nonsurvivors (n = 23, 61%) had been less frequently successfully revascularized, exhibited more frequently renal failure, needed higher vasopressor doses, and presented with significantly higher interleukin-6 plasma concentrations on intensive care unit admission than 30-day survivors. Univariate hazard ratios (95% confidence interval) for 30-day mortality were 1.49 (1.24-1.80) for every 50 pg/mL increase in the interleukin-6 plasma concentration (p = .00003), 1.06 (1.02-1.10) for every 0.1 microg x kg x min increase in the total vasopressor dose (p = .007), 1.14 (1.04-1.25) for every mmol/L increase in serum lactate (p = .006), 2.47 (1.06-5.73) for acute renal failure (p = .036), and 0.34 (0.14-0.82) for successful revascularization (p = .016). However, interleukin-6 plasma concentrations were correlated with vasopressor need and were significantly higher in patients with acute renal failure and in patients without or unsuccessful revascularization. In a multivariate Cox-proportional hazard model, interleukin-6 was the only significant predictor of 30-day mortality with a hazard ratio of 1.42 (1.12-1.80, p = .004). Accordingly, interleukin-6 concentrations > or =200 pg/mL (the point of maximum interest by receiver operating characteristic analysis with a specificity of 87% and a sensitivity of 74%) were associated with a significantly increased 30-day mortality rate in both patients with and patients without successful revascularization.
CONCLUSIONS: Interleukin-6 concentrations are an independent predictor of 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775569     DOI: 10.1097/01.CCM.0000228919.33620.D9

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

Review 1.  Vasopressors for acute myocardial infarction complicated by cardiogenic shock.

Authors:  R Prondzinsky; K Hirsch; L Wachsmuth; M Buerke; S Unverzagt
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-12-04       Impact factor: 0.840

2.  Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia.

Authors:  Ignacio Martín-Loeches; Jordi Solé-Violán; Felipe Rodríguez de Castro; M Isabel García-Laorden; Luis Borderías; José Blanquer; Olga Rajas; M Luisa Briones; Javier Aspa; Estefanía Herrera-Ramos; José Alberto Marcos-Ramos; Ithaisa Sologuren; Nereida González-Quevedo; José María Ferrer-Agüero; Judith Noda; Carlos Rodríguez-Gallego
Journal:  Intensive Care Med       Date:  2011-11-24       Impact factor: 17.440

Review 3.  Cardiogenic shock in ACS. Part 1: prediction, presentation and medical therapy.

Authors:  Stephen Westaby; Rajesh Kharbanda; Adrian P Banning
Journal:  Nat Rev Cardiol       Date:  2011-12-20       Impact factor: 32.419

4.  Hypothermia in cardiogenic shock reduces systemic t-PA release.

Authors:  Jesper van der Pals; Michael I Götberg; Matthias Götberg; Lillemor Mattsson Hultén; Mia Magnusson; Sverker Jern; David Erlinge
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 5.  Interleukin-6 in surgery, trauma, and critical care part II: clinical implications.

Authors:  Randeep S Jawa; Sergio Anillo; Kristin Huntoon; Heinz Baumann; Mahmoud Kulaylat
Journal:  J Intensive Care Med       Date:  2011 Mar-Apr       Impact factor: 3.510

6.  Association of Lymphocyte to Monocyte Ratio and Risk of in-Hospital Mortality in Patients with Cardiogenic Shock: A Propensity Score Matching Study.

Authors:  Zhengwei Zhang; Qionghua Hu; Tianyang Hu
Journal:  Int J Gen Med       Date:  2021-08-12

Review 7.  Clinical significance of lactate in acute cardiac patients.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2015-08-26

8.  Predictors of mortality in patients with cardiogenic shock treated with primary percutaneous coronary intervention and intra-aortic balloon counterpulsation.

Authors:  B Schwarz; M Abdel-Wahab; D R Robinson; G Richardt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-23       Impact factor: 0.840

9.  A microarray analysis of temporal gene expression profiles in thermally injured human skin.

Authors:  J A Greco; A C Pollins; B E Boone; S E Levy; L B Nanney
Journal:  Burns       Date:  2009-09-24       Impact factor: 2.744

10.  Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients.

Authors:  Nicolas Mongardon; Virginie Lemiale; Sébastien Perbet; Florence Dumas; Stéphane Legriel; Sylvie Guérin; Julien Charpentier; Jean-Daniel Chiche; Jean-Paul Mira; Alain Cariou
Journal:  Intensive Care Med       Date:  2009-10-21       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.